Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1597)	10/4/2008 2:53:38 PM
From: Tomato	Read Replies (1) \| Respond to of 1833

Seems to me that Blitz said that KDUS concluded that they had no interest in the Solvay/ISIP thing. If this is the case and they're wrong, than shouldn't something be done? I don't recall seeing any public documents in the past 8+ years since I've owned KDUS that indicates anything about the issue. You have anything in print to prove them wrong? MOAB must have the most juice of any SHs now and I'm sure would be interested if someone's trying to pull a fast one (or if there's a strange case of collective amnesia going around in NY). Unfortunately, my Googling hasn't turned up any phone number for them ...Think there must be an address for them... I'm not even sure what I'd say to MOAB..."I hear tell that KDUS might have an royalty interest in SLV-320 by Solvay that KDUS should own through a long ago deal with OSIP, but nobody I talk to at KDUS seems to know about it. The current CEO apparently had KDUS's attys. write OSIP who replied that KDUS has no interest. However, a long time SH I know says KDUS indeed does have an interest, but I've got nothing in writing anywhere to prove this.... hmmm...

To: scaram(o)uche who wrote (1597)	10/4/2008 5:34:45 PM
From: Tomato	Respond to of 1833

Here's some info on MOAB if "anyone" should want to give them a call and explain the ins and outs like only "anyone" can. :-) Richard A. Silberberg Moab Capital Partners, LLC 15 East 62nd Street New York, NY 10021 (212) 981-2645

To: scaram(o)uche who wrote (1597)	10/5/2008 12:11:37 PM
From: rkrw	Read Replies (2) \| Respond to of 1833

FYI, from a publication I subscribe to. SOLVAY’s SLV-320, an adenosine A1 receptor antagonist Dr. Veselin Mitrovic of Germany reported on a randomized, double-blind, parallel-group, Phase II study of SLV-320, but the data didn’t look very promising in NYHA Class II-III patients with LVEF =35%. In fact, on almost every measure, SLV-320 (5 mg, 10 mg, or 15 mg IV over 60 minutes) performed significantly poorer than furosemide 40 mg IV bolus or placebo.